Leica Biosystems Receives FDA's Enforcement Discretion For Use Of Aperio ImageScope DX Viewing Software For Remote Diagnosis During COVID-19 Emergency

VISTA, Calif., April 3, 2020 /PRNewswire/ -- Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received notification from the U.S. Food & Drug Administration (FDA) that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use.